Objective To update the estimated global incidence of Japanese encephalitis (JE) using recent data for the purpose of guiding prevention and control efforts.
Introduction
Japanese encephalitis (JE) is among the most important viral encephalitides in Asia, especially in rural and suburban areas where rice culture and pig farming coexist. [1] [2] [3] It has also occurred rarely and sporadically in northern Australia and parts of the Western Pacific. [4] [5] [6] JE is due to infection with the JE virus (JEV), a mosquito-borne flavivirus. The main JEV transmission cycle involves
Culex tritaeniorhynchus mosquitoes and similar species that lay eggs in rice paddies and other open water sources, with pigs and aquatic birds as principal vertebrate amplifying hosts. 1, 2, 7 Humans are generally thought to be dead-end JEV hosts, i.e. they seldom develop enough viremia to infect feeding mosquitoes. Fewer than 1% of human JEV infections result in JE.
Approximately 20-30% of JE cases are fatal and 30-50% of survivors have significant neurologic sequelae. 8 JE is primarily a disease of children and most adults in endemic countries have natural immunity after childhood infection, but all age groups are affected. In most temperate areas of Asia, JEV is transmitted mainly during the warm season, when large epidemics can occur. In the tropics and subtropics, transmission can occur year-round but often intensifies during the rainy season. [1] [2] [3] The global incidence of JE is unknown because the intensity and quality of JE surveillance and the availability of diagnostic laboratory testing vary throughout the world.
Countries that have implemented high-quality childhood JE vaccination programmes have seen a dramatic decline in JE incidence. Although JE is reportable to the World Health Organization (WHO) by its Member States, reporting is highly variable and incomplete. In the late 1980s, Burke and Leake estimated that 50 000 new cases of JE occurred annually among the 2.4 billion people living in the 16 Asian countries considered endemic at the time (approximate overall annual incidence: 2 per 100 000). 2 In the intervening two decades, despite major population growth, urbanization, changes in agricultural practices and increased use of the JE vaccine in many countries, this figure has been widely quoted, including very recently. [9] [10] [11] [12] [13] In 2000, Publication: Bulletin of the World Health Organization; Type: Research Article ID: BLT.10.085233
Page 3 of 22 assuming an annual, age-group-specific incidence of 25 cases per 100 000, Tsai estimated that in the absence of vaccination 175 000 cases of JE would occur annually among Asian children aged 0-14 years living in rural areas. 14 The current study used more recent, published, local or national incidence estimates and current population data to produce an updated estimate of the annual global incidence of JE.
Methods
We approximated the JE-affected territory of each of the 24 countries endemic for JE using a recent update 15 of an earlier approximation by Tsai 16 with some modifications (Table 1) . Based on these same approximations, 15, 16 we then stratified the JE-affected territory of some countries (e.g. China [excluding Taiwan], India and Nepal) into two or more incidence strata. Because suitable studies of JE incidence were not available for every endemic country or incidence stratum, we sorted JE-endemic countries and incidence strata into 10 incidence groups (A, B, C1, C2 and D through I) based primarily on geographic proximity, ecologic similarity, vaccine programme similarity. 
Incidence data
We identified studies that contained potentially useful data on the incidence of JE in Asia in a manner similar to the one used in a recent study of global typhoid fever incidence. 21 Whenever possible, this review followed the relevant guidelines for Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). 22 The review process is described as follows and no protocol is available. We conducted a MedLine search of papers in any language published between 1985 (arbitrarily chosen to emphasize recent data) and April 2010. We used the following search strategy and keywords: Japanese encephalitis and (incidence or prevalence or public health or surveillance or distribution or epidemiology approximately 75 references by selecting only those that contained explicit human JE incidence data or data that could be used to calculate incidence. Additional references were sought from these papers' reference lists and from the collections of the authors (including several papers recently submitted or "in press"), and this yielded a total of 80 references of interest. Each of these papers (or the English translation of five Chinese-language papers) was then carefully reviewed by at least two authors to further cull the list, resulting in a final group of 12 studies that provided original, recent population-based and largely laboratory-confirmed incidence data (or hospital-based incidence data in a defined population). 13, 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] These 12 studies consisted of one study each from Bangladesh, Cambodia, Indonesia, Malaysia and Thailand, two from China (excluding Taiwan) two from Japan and three from Nepal. They represented all but three (B, E and I) of the 10 incidence groups ( Table 1 ). Fig. 1 shows the approximate locations of the study sites in each primary reference. Point estimates of the annual JE incidence in each primary reference are shown as cases per 100 000 persons ( Table 2) . We used an Excel spreadsheet for all calculations in this study.
Population data
For each endemic country, we obtained the total population and that of the approximate JEaffected area from the country's official web site (as identified through www.GeoHive.com). We used the most recent census data (1998-2011) or official inter-census estimates (2000-2010) and dichotomized age as follows: children, aged 0-14 years; adults, aged  15 years (Table 1) . For each country, the estimated total population aged 0-14 years was based on percentages for 2010 obtained from the United Nations 33 (for Taiwan, China, the percentage was obtained from The world factbook 34 ). Because a concise source of such percentages for JE-endemic administrative divisions and subdivisions of countries was not available, we assumed that the age distribution within each country was homogeneous.
Assumptions by incidence group
In unvaccinated populations in endemic areas, JE is largely a paediatric disease and most people have acquired active immunity by adulthood. Conversely, in areas with long-standing, highquality childhood vaccination programmes, JE is usually a rare disease of non-immune adults, especially the elderly. A transitional phase in which the incidence of JE in children and adults is about the same can also occur. 3 Because many of our primary references provided point estimates of JE incidence for all age groups combined or for children only (generally 0-14-yearolds), assumptions about age-specific JE incidence were often necessary. We had to make additional assumptions because of the absence of appropriate primary references for incidence groups B, E and I. We assumed that in some countries with a historically non-homogeneous distribution of JE risk (e.g. plain versus highland areas of Sri Lanka and northern versus southern portions of Thailand), the preferential use of vaccine in areas that were formerly higher-risk has homogenized the risk countrywide. Incidence groups are described in Table 1 (available at: http://www.who.int/bulletin/volumes/88/##/##-######) and additional group-specific assumptions are summarized as follows:
Overall incidence is 0.003 per 100 000; the child (aged  14 years) to adult (aged > 14 years) case frequency ratio is 7:1 (based on visual inspection of a figure in the report by Arai et al. 23 ). Because this study 23 and the study by Hashimoto et al. 24 overlapped in time and because both were based on national surveillance, a weighted average of their respective results could not be used. Therefore, we used the incidence estimate by Arai et al. in our analysis but included the study by Hashimoto et al. in Table 2 (available at: http://www.who.int/bulletin/volumes/88/##/##-######) for completeness and as general validation of the results obtained by Arai et al.

Incidence Group B: JE is rare, with an overall incidence of 0.003 per 100 000, i.e. the authors assumed it to be the same as in historically high-incidence areas with longstanding, high-quality vaccination programmes (i.e. Incidence Group A); the child to adult case frequency ratio is 7:1.
23
 Incidence Group C1: Overall incidence is 3.3 per 100 000 (weighted average of results from Yin et al. 20 and Xufang et al. 13 ); the child to adult case frequency ratio is 3:1 (based on the ratio of 156 cases in 0-14-year-olds to 57 cases in persons aged > 14 years among combined residents and non-residents, as reported by Yin et al. 20 ).
 Incidence Group C2: Overall incidence is 0.01 per 100 000; the child to adult case frequency ratio is 3:1 (as for Incidence Group C1).


Incidence Group D:
Incidence in children aged 12-14 years is the same as in children aged 0-11 years; incidence in children aged 0-14 years is 10.6 per 100 000 (weighted average of results from Touch et al., 25 Kari et al. 26 and Hoke et al. 27 ); the child to adult case frequency ratio is 7:1 (based on the ratio of 43 childhood cases to 6 adult cases detected from July 2001 through 2006 by Wong et al. 32 ).

Incidence Group E: Age-specific incidences in this group are assumed by the authors to be half as high as in incidence group D.
 Incidence Group F: Overall incidence is 2.8 per 100 000 (approximate weighted average of results from two studies from Nepal 28, 29 ); the child to adult case frequency ratio is 5:4 (based on the ratio of 532 cases in 0-14-year-olds to 419 cases in persons aged > 14 years, as reported by Wierzba et  Incidence Group H: Overall incidence is 1.5 per 100 000 (based on 49 cases per 600 000 persons over a 5.5-year period in the study by Wong et al.); incidence in children aged 12-14 years is the same as in children aged 0-11 years; the child to adult case frequency ratio is 7:1.
32
 Incidence Group I: Overall incidence is 3.3 per 100 000 (based on the average annual incidence of 6.5 per 100 000 in nearby Taiwan, China, during the immediate prevaccination era [1965] [1966] [1967] , 35 reduced by 50% following a national mass-vaccination campaign among children in 2009); the child to adult case frequency ratio is 7:1.
Results
Based on the assumptions noted above, we estimated that approximately 67 900 JE cases typically occur annually in the 24 JE-endemic countries, for an incidence of 1.8 per 100 000 overall (Table 3) . Approximately 33 900 (50%) of these cases occur in China (excluding Taiwan) 
Discussion
In the pre-JE-vaccination era, tens of thousands of JE cases were often reported annually in Asia.
During 1965-1975, more than 1 million cases were reported in China alone. 1 In Japan, the 36 While these data almost certainly include some non-JE cases that were clinically misclassified without the benefit of laboratory confirmation, they almost certainly also represent significant under-reporting of true cases.
1,14
The results of the current study suggest that the actual incidence of JE is nearly 10 times higher Haemophilus influenzae type b disease and streptococcal disease. 21, 43, 44 Our study is therefore subject to many of the same limitations. First, we derived estimates from sparse data of variable quality, with some notable exceptions (e.g. data from Japan). Furthermore, useful data were lacking from several important countries or parts of countries. The absence of data from India is particularly worrisome because the country has a very large population and several diverse JEendemic regions Although we did not feel that a formal sensitivity analysis was essential to enable us to appropriately interpret our results, these results would obviously be highly sensitive to relatively small changes in some input data, especially for China and India, which together contain approximately two thirds of the world's population at risk for JE. This is particularly true for Incidence Group C1 (the higher-incidence stratum of China), which accounted for half of our estimated global total of annual JE cases, and, to a lesser extent, for incidence groups D, F and H (much of India and south-eastern Asia). In contrast, our results would be far less sensitive to changes in input data for incidence groups A, B, C2 and I. Another limitation of our approach is that some of the 12 key references for JE incidence involved hospital-based surveillance in imperfectly defined catchment areas. Such studies tend to underestimate true incidence because they depend on all true cases being hospitalized (as opposed to being treated as outpatients) and within their residential catchment area. Other studies relied on an incomplete network of sentinel hospitals and are similarly subject to an underreporting bias, although such a bias is not readily quantifiable. The following are also potential sources of error that are difficult to quantify: (i) a lack of standardized laboratory testing methods (e.g. the use of various commercially available or in-house test kits for the detection of anti-JEV immunoglobulin M antibody); (ii) incomplete collection of clinical samples (e.g. failure to collect and test both acute-and convalescent-phase samples in all suspected cases, resulting in some degree of underdiagnosis); and (iii) the cocirculation of other cross-reactive flaviviruses (especially dengue viruses) in some JE-endemic areas We did not attempt to distinguish between urban and rural incidence because few, if any, of the studies on which our results were based broke down incidence in this way. They involved surveillance in whole countries or in areas that included a mix of urban and rural populations.
Nevertheless, the risk of JE continues to be strongly associated with exposure in rural and, to a lesser extent, suburban areas. 3 Another limitation of our approach is that JE is an ecologically complex epidemic as well as endemic disease and therefore does not exist in a steady-state, even IG, incidence group.
a The total population (endemic + non-endemic areas) aged 0-14 years is 1000.9 million, aged 15+ years is 2692.7 million, and combined is 3693.6 million (country-specific data not shown). a Total population (endemic + non-endemic areas) aged 0-14 years is 1000.9 million; aged  15 years, 2692.7 million; and combined, 3693.6 million (country-specific data not shown).
b Per 100 000.
c Total frequency divided by 67 897 times 100.
Note: See text for assumptions.
